ALKEMNSEAlkem Laboratories Limited· Pharmaceuticals & BiotechnologyHighNegative
Announced Tue, 30 Dec, 2025 · 16:08 IST

Alkem Laboratories Limited has informed the Exchange about Action(s) initiated or orders passed

ALKEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+0.7%Reaction day
₹5432.00
prior close
₹5450.00
announcement price
After-mkt
timing
Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+1.0%-0.3% vs market
Pharmaceuticals peers, median of 156sector+0.8%-0.1% vs sector

On the reaction day the stock moved 0.3 pts less than Nifty Midcap 150 and 0.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.1
10m
+0.2
15m
+0.2
30m
-0.1
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+0.7+1.0-0.3+0.8-0.1
Next day
+0.6+1.4-0.8+0.8-0.1
2d
+2.8+2.3+0.5+1.9+1.0
3d
+2.5+2.2+0.3+1.4+1.2
4d
+4.1+2.0+2.1+1.3+2.8
5d
+6.6+2.5+4.2+2.1+4.6
1w
+6.5-0.3+6.9-1.1+7.6
15d
+5.8-3.1+8.9-4.3+10.1
1m
+1.5-3.7+5.2-5.4+7.0
2m
+2.8-2.7+5.4-7.2+10.0
3m
-3.3-9.9+6.6-13.0+9.7
UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Alkem Laboratories has received a GST demand order from the Deputy Commissioner, Large Taxpayer Unit (Corporate Division, West Bengal) for FY 2021-2022. The order demands GST of Rs. 5.21 lakh, interest of Rs. 3.89 lakh, and a penalty of Rs. 62,098, totaling roughly Rs. 9.72 lakh. The tax authority has alleged that the company wrongly used the Reverse Charge Mechanism and excessively claimed Input Tax Credit. The company disagrees with the demand and plans to file an appeal. Alkem has stated that there is no material impact on its financial, operational, or other activities.

Likely market impact

The financial impact is very small and the company itself says it is not material, so this is unlikely to affect the stock price or shareholders meaningfully. The appeal process may take time, but the disclosure is largely procedural.